PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

PTC Therapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT – Research Report), ALX Onc...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (PTCT), ALX Oncology Holdings (ALXO) and Encompass Health (EHC)

Wells Fargo analyst Tiago Fauth maintained a Buy rating on PTC Therapeutics today and set a price target of $93.00. Fauth covers the Healthcare sec...

PTC Therapeutics (PTCT) Gets a Buy from Wells Fargo

Goldman Sachs analyst Paul Choi maintained a Sell rating on PTC Therapeutics today and set a price target of $55.00. According to TipRanks, Choi is...

PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs

SanDisk ($SNDK) stock gained 13.3% in regular trading on November 24 and rose another 7.3% in after-hours trading following a series of positive de...

Market Cap	$5.27B	P/E Ratio	8.93
52W High	$87.50	52W Low	$35.95
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	14.0%	52W Position	77.0%
Overall Score	58	Value Score	60
Quality Score	60	Technical Score	54

EPS Current Est	$8.47	EPS Next Est	$-1.48
EPS Growth Est	-117.5%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTCT	$75.64	+0.27%	897.94K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PTCT	$75.64	+0.3%	897.94K
3
4
5
6

PTCT

PTCT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get PTC Therapeutics Inc. Data in Excel

Get PTC Therapeutics Inc. Data in Excel